ArticleFrontiers in oncology2024

Retrospective analysis of survival and safety of bevacizumab biosimilar and original drug combination chemotherapy in non-small cell lung cancer.

Xinyi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.